share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K：重大事件
美股SEC公告 ·  08/14 16:08
Moomoo AI 已提取核心信息
On August 13, 2024, Avalo Therapeutics, Inc. held its annual stockholders meeting where several key proposals were voted upon. The stockholders approved the Fourth Amended and Restated 2016 Equity Incentive Plan, which increases the total number of shares reserved for issuance to 3,548,882, extends the automatic increase in shares through January 1, 2034, and bases the increase on 5% of the outstanding common and Series C Preferred Stock, plus outstanding prefunded warrants as of the end of the previous year. Additionally, the Amended and Restated Employee Stock Purchase Plan was approved, increasing the reserved shares to 234,878 and extending the automatic annual increase with similar terms. The Board had previously approved these plans on June 6, 2024, pending stockholder approval. During the meeting, seven board members were elected to serve until the 2025 Annual Meeting, and the issuance of shares for various purposes including the conversion of Series C Preferred Stock and the exercise of warrants was approved. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
On August 13, 2024, Avalo Therapeutics, Inc. held its annual stockholders meeting where several key proposals were voted upon. The stockholders approved the Fourth Amended and Restated 2016 Equity Incentive Plan, which increases the total number of shares reserved for issuance to 3,548,882, extends the automatic increase in shares through January 1, 2034, and bases the increase on 5% of the outstanding common and Series C Preferred Stock, plus outstanding prefunded warrants as of the end of the previous year. Additionally, the Amended and Restated Employee Stock Purchase Plan was approved, increasing the reserved shares to 234,878 and extending the automatic annual increase with similar terms. The Board had previously approved these plans on June 6, 2024, pending stockholder approval. During the meeting, seven board members were elected to serve until the 2025 Annual Meeting, and the issuance of shares for various purposes including the conversion of Series C Preferred Stock and the exercise of warrants was approved. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
2024年8月13日，Avalo Therapeutics, Inc. 召开了股东年会，对几项重要提案进行了投票。股东批准了《第四次修订和重申2016年股权激励计划》，其中增加了被保留用于发行的股份数量，达到了3,548,882股，将自动增加股份的期限延长至2034年1月1日，并基于上一年底的已发行普通股和C系列优先股、以及已发行预发行认股证的5%的比例增加。另外，《修订和重申员工股票购买计划》也获得了批准，将被保留的股票增加到234,878股，并延长了类似的自动年度增加条款。董事会之前在2024年6月6日批准了这些计划，前提是获得股东的批准。在会议期间，选举了七位董事会成员，任期至2025年股东年会，并批准发行股票，用于各种目的，包括转换C系列优先股和行使认股证。股东还核准了Ernst & Young LLP作为独立注册会计师事务所，负责截至2024年12月31日的财年审计工作。
2024年8月13日，Avalo Therapeutics, Inc. 召开了股东年会，对几项重要提案进行了投票。股东批准了《第四次修订和重申2016年股权激励计划》，其中增加了被保留用于发行的股份数量，达到了3,548,882股，将自动增加股份的期限延长至2034年1月1日，并基于上一年底的已发行普通股和C系列优先股、以及已发行预发行认股证的5%的比例增加。另外，《修订和重申员工股票购买计划》也获得了批准，将被保留的股票增加到234,878股，并延长了类似的自动年度增加条款。董事会之前在2024年6月6日批准了这些计划，前提是获得股东的批准。在会议期间，选举了七位董事会成员，任期至2025年股东年会，并批准发行股票，用于各种目的，包括转换C系列优先股和行使认股证。股东还核准了Ernst & Young LLP作为独立注册会计师事务所，负责截至2024年12月31日的财年审计工作。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息